For cancer patients, medicines are given Clinical trials may help save or extend lives.
but despite thousands Tested each year only in the United States 3% to 5% Eligible patients enroll in trials of new treatments.
TriomixA generic AI startup claims it can significantly reduce the time it takes doctors to match patients with tests.
Doctors’ recommendations are often important for enrolling patients. However, busy oncologists and nurses often do not have time to learn about all the diagnostic tests that may be right for their patients.
I’m not a doctor, so I don’t know the day-to-day challenges of oncology medical staff. But unfortunately I know from personal experience how hard it is for cancer patients to find clinical trials. When my father was sick, I spent countless hours on ClinicalTrials.gov, a website and database that lists thousands of ongoing trials. And just in March, I spent half a Saturday finding clinical trials for a friend of mine who has stage IV cancer. Her doctor only offered one test, so she asked me if there were other options.
Because most clinical trials have complex criteria, there are often dozens of factors to consider for eligibility, such as cancer stage, mutations, and previous treatments. Medical staff often require hours to manually review a patient’s medical records to find an appropriate diagnostic test. But due to a shortage of oncology professionals, many cancer patients are not offered participation or miss their eligibility threshold.
Triomics was founded by former MIT biotech researcher Sarim Khan and Adobe AI scientist Hridayraj Singh. The pair, who have been friends since college, decided to create Triomics in 2021 after realizing that advances in generative AI and LLM could help extract data from electronic health records (EHRs) in minutes instead of hours. This could help find appropriate clinical trials for cancer patients in the U.S. ,
Khan and Singh joined Y Combinator in winter 2021 and began working on an LLM built specifically for cancer centers and oncology departments in hospital systems.
Three years later, Triomics says six cancer centers and hospitals are actively using or piloting its LLM, and it plans to double that number by the end of the year. And now the company has raised a $15 million Series A from Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator to help it grow its platform and bring it to new customers.
While reducing the time it takes to match patients with clinical trials may seem to be the most immediately valuable application of Triomics software, Khan says Triomics is much more than a clinical trials company. “Doctors use it in so many different use cases that I could go on over and over again,” he said.
After Triomics’ LLM, which the company is calling OncoLLM, “reads” the patient’s medical record, using the data to help doctors and other medical staff prepare for a patient’s visit or provide details of the affected organs and stage. Can be used to help present cancer data. Progress of state regulatory agencies.
Of course, Triomix is not alone in tackling this area. Other startups doing AI clinical trial matching include Deep 6 AI, QuantHealth, trajectory, among Other,
But Khan believes Triomics is one of the few startups that processes large-scale datasets specifically for cancer centers.
triomics-raises-15m-series-a-to-automate-cancer-clinical-trials-matching-techcrunch
